Vericel stock hits 52-week high at 47.15 USD
Vericel Corporation's stock reached a new 52-week high of $47.15, marking a 30% year-to-date return and a 19.16% increase over the last 12 months. This achievement follows strong Q1 2026 financial results, where the company surpassed EPS and revenue expectations. InvestingPro analysis suggests the stock may still be undervalued despite its recent gains.
Vericel CMO Jonathan Hopper sells $450,000 in company stock By Investing.com
Vericel's Chief Medical Officer, Jonathan Hopper, sold 10,000 shares of company stock for $450,000 but also acquired 10,000 shares through option exercises for $298,200. These transactions occurred while Vericel's stock traded near its 52-week high, with an InvestingPro analysis suggesting it remains undervalued. The company recently reported strong Q1 2026 financial results, exceeding both earnings and revenue expectations.
Vericel (VCEL) CMO exercises options, sells 10,000 shares under 10b5-1 plan
Vericel Corp's Chief Medical Officer, Jonathan Mark Hopper, executed a pre-scheduled transaction on June 26, 2026, exercising options for 10,000 shares at $29.82 each and simultaneously selling those 10,000 shares on the open market for $45.00 per share. These sales were conducted under a Rule 10b5-1 trading plan adopted in May 2025. Following the transaction, Hopper retains 75,753 direct shares and 25,000 stock options, demonstrating continued equity exposure to the company.
Vericel (VCEL) accounting officer sells 2,732 shares, exercises options
Vericel Corp's Principal Accounting Officer, Jonathan Siegal, exercised 2,500 stock options and sold a total of 2,732 common shares at $44.90 per share on June 26, 2026. These transactions, which generated $122,667, were pre-arranged under a Rule 10b5-1 trading plan. After these sales, Siegal holds 886 common shares and 6,500 outstanding stock options.
Vericel (VCEL) CFO executes 5,000-share Rule 10b5-1 stock sale
Vericel's CFO, Mara Joseph Anthony Jr., sold 5,000 shares of common stock at $44.75 per share on June 26, 2026, as part of a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. Following this transaction, he directly holds 16,009 shares. The sale, valued at $223,750, was an open-market transaction and included shares acquired through an employee stock purchase plan.
Form 4 Vericel Corp Ord For: 30 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Vericel Corp Ord for the period ending June 30. It provides the news without further details, alongside various market data and other news headlines. The Form 4 filing is a standard SEC document indicating changes in beneficial ownership of a company's securities by its directors, officers, or significant shareholders.
Vericel (VCEL) Chief Legal Officer sells 15,000 shares after option exercise
Vericel Corp's Chief Legal Officer, Sean C. Flynn, exercised stock options for 15,000 shares at $16.25 and subsequently sold them at an average price of $45.64 per share. These transactions, which occurred on June 26, 2026, were conducted under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. Following these sales, Flynn directly holds 1,647 shares of Vericel common stock.
Vericel CMO Jonathan Hopper sells $450,000 in company stock
Vericel Corp's Chief Medical Officer, Jonathan Hopper, sold 10,000 shares of company stock worth $450,000 but also acquired 10,000 shares through option exercises for $298,200. These transactions occurred while the stock was near its 52-week high, despite analysis suggesting it remains undervalued with potential upside. The company recently reported strong Q1 2026 results, exceeding revenue and EPS expectations.
Vericel chief legal officer Sean Flynn sells $684,600 in shares
Vericel's Chief Legal Officer, Sean C. Flynn, sold 15,000 shares of the company's common stock for $684,600 as part of an automatic trading plan. Concurrently, he exercised stock options to acquire 15,000 shares for $243,750. These transactions follow a strong first quarter for Vericel, with the stock trading near its 52-week high and considered undervalued by InvestingPro.
VCEL (NASDAQ) insider sale: Joseph A. Mara sold 5,000 shares for $202,500
Joseph A. Mara, an insider at Vericel Corp (VCEL), sold 5,000 shares of common stock for $202,500 on May 7, 2026, as reported in a Form 144 SEC filing. The filing also indicated a proposed sale of an additional 5,000 shares and listed several restricted stock vesting entries dating back to 2023 and 2025 as compensation. This transaction is considered neutral in terms of filing sentiment and impact.
VCEL proposed share resale and recent insider trades (NASDAQ: VCEL)
A recent SEC Form 144 filing for Vericel Corp (NASDAQ: VCEL) indicates proposed resales and recent insider transactions. The filing details a restricted stock vesting of 232 shares planned for resale on February 18, 2026, and a stock option exercise of 2,500 shares on June 26, 2026. Additionally, it highlights two open-market sales by Jonathan D. Siegal in early May 2026, totaling 4,855 shares for approximately $188,045.
15,000-Share Option Exercise Reported for Vericel (NASDAQ: VCEL)
Vericel (NASDAQ: VCEL) reported a 15,000-share option exercise on June 26, 2026, totaling an aggregate value of $684,659.03 through Fidelity Brokerage Services LLC. This Form 144 filing also noted a prior sale of 15,000 shares by Sean C. Flynn on June 18, 2026, for $603,148.50. The filing is a routine disclosure of option-derived share sales.
VCEL [144] Vericel Corp SEC Filing
Vericel Corp (VCEL) submitted a Form 144 disclosing the sale of 10,000 shares of Common Stock via a stock option exercise on June 26, 2026. The filing also detailed prior dispositions by Jonathan M. Hopper, involving 3,472 shares on April 2, 2026, for $121,520 and 4,375 shares on June 2, 2026, for $153,125. The Form 144 is a regulatory document providing transparency on the proposed sale of restricted or control securities.
Form 144 Vericel Corp For: 26 June By Investing.com
This article reports on the Form 144 filing for Vericel Corp (VCEL) on June 26. It mentions that Vericel Corp's stock was up 7.76% and provides general market data and related news without further details on the specific Form 144 filing.
Vericel Corp (VCEL) Financial Health: Profitability & Balance Sheet Analysis
Vericel Corp (VCEL) currently holds a robust financial score of 7.97, ranking 89th out of 157 in the Pharmaceuticals industry, indicating strong financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 30.09% to $68.42 million and a net profit increase of 43.96%. Detailed financial components like cash and cash equivalents, total assets, and free cash flow were not disclosed, but the overall assessment reflects solid growth potential and operational performance.
Vericel Corp (VCEL) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Vericel Corp (VCEL), indicating its current valuation score is 7.01, ranking 139 out of 157 in the Pharmaceuticals industry. The P/E ratio stands at 94.07, which is significantly below its recent high but above its recent low. Key valuation metrics like P/B, P/S, and P/CF are not yet disclosed by the company.
VCEL Financials: Revenue Breakdown, Margins & Competitor Comparison
The article provides a financial analysis of Vericel Corp (VCEL), detailing its revenue breakdown, profitability margins, and a comparison with competitors. MACI is the primary revenue driver, contributing 82.4% of total sales. VCEL's financial health is further assessed through its gross, operating, and net margins, alongside its Return on Equity and competitive benchmarking against BHVN and NKTR.
Vericel (VCEL) COO exercises options, sells 10,000 shares under 10b5-1 plan
Vericel Corp's Chief Operating Officer, Michael Halpin, exercised options to acquire 10,000 shares of common stock at $16.66 per share and subsequently sold them at $40.24 per share on June 18, 2026. This transaction was pre-arranged under a Rule 10b5-1 trading plan adopted on December 2, 2025. Following these sales, Halpin directly holds 16,248 shares of Vericel common stock.
Vericel (NASDAQ: VCEL) CLO exercises options and sells 15K shares
Vericel's Chief Legal Officer, Sean C. Flynn, exercised options to acquire 15,000 common shares at $16.25 per share and subsequently sold all 15,000 shares at an average price of $40.21 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. Following these sales, Flynn retains 1,647 common shares and 70,000 unexercised stock options.
[144] Vericel Corp SEC Filing
This article reports a Form 144 SEC filing by Vericel Corp (VCEL) on June 18, 2026, indicating a proposed sale of 15,000 shares of common stock acquired through a stock option exercise, valued at $603,148.23. The filing details the transaction and confirms no prior sales within the last three months by the filer. It includes standard SEC disclaimers regarding intentional misstatements.
Vericel Corp (VCEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Vericel Corp (VCEL) by business segment and region. As of FY2024, the company's revenue heavily relies on its MACI product (86.70%), followed by Epicel (11.61%) and NexoBrid (1.70%). All reported revenue originates from the United States.
Vericel Corp (VCEL) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Vericel Corp (VCEL), outlining both major individual shareholders and the types of institutional investors holding its stock. It provides a breakdown of proportional holdings by firms like BlackRock, State Street, and Vanguard, alongside an overview of institutional shareholding changes over recent quarters. The report also lists several related ETFs that include VCEL.
Vericel Corp (VCEL) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Vericel Corp (VCEL)'s dividend and stock split history. It notes that the company has not distributed any dividends over the past five years and has no recorded stock splits. The page also displays current stock information such as market cap and P/E ratio.
Vericel Corp (VCEL) Institutional Confidence
Vericel Corp (VCEL) has a high institutional shareholding score of 10.00, placing it first in the Pharmaceuticals industry. Institutional shareholding has increased by 11.74% quarter-over-quarter, with BlackRock and State Street being among the top institutional holders. Steven Cohen is the largest individual institutional shareholder, holding 154.07K shares.
Vericel Corp (VCEL) Earnings Forecast: Future EPS & Revenue Growth Estimates
Vericel Corp (VCEL) has an earnings forecast score of 8.50, ranking 34th in the Pharmaceuticals industry. Analysts have an average price target of $55.00 for VCEL, with the majority recommending a "Buy" trend. The company's expected revenue for the next quarter is $72.69 million, and the EPS for the previous quarter was $0.46, with the next quarter's EPS expected at -$0.03.
Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Vericel (VCEL)
This article provides an overview of analyst ratings for two healthcare companies, Rezolute (RZLT) and Vericel (VCEL). Douglas Tsao from H.C. Wainwright reiterated a Buy rating for Rezolute with a $5.00 price target, while Josh Jennings from TD Cowen reiterated a Buy rating for Vericel with a $55.00 price target. Both companies maintain a Strong Buy consensus rating among analysts, with significant upside potential noted for Rezolute.
Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Vericel (VCEL)
Two analysts from the Healthcare sector have issued bullish sentiments on Rezolute (RZLT) and Vericel (VCEL). H.C. Wainwright reiterated a Buy rating for Rezolute with a $5.00 price target, while TD Cowen reiterated a Buy rating for Vericel with a $55.00 price target. Both companies also received "Strong Buy" consensus ratings from analysts overall.
How to watch Vericel's June 16 Truist MedTech talk online
Vericel (NASDAQ: VCEL) announced it will present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026. A live webcast of the presentation will be accessible through the Investor Relations section of Vericel's website. The company's stock saw a 4.14% gain on the day this news was published, reflecting a moderate positive market reaction despite general market volatility.
Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026
Vericel Corporation announced it will present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026. A webcast of the presentation will be available on the Investor Relations section of the Company's website. Vericel is a leader in advanced therapies for sports medicine and severe burn care markets, marketing products like MACI, Epicel, and NexoBrid.
Vericel (VCEL) CMO sells 4,375 shares after option exercise
Vericel Corp's Chief Medical Officer, Jonathan Mark Hopper, exercised stock options for 4,375 shares at $16.66 per share and simultaneously sold those 4,375 shares at $35.00 per share. These transactions were executed automatically under a pre-arranged Rule 10b5-1 trading plan. After the sales, Hopper directly holds 75,753 shares of Vericel common stock and retains 1,625 stock options.
Proposed sale of 4,375 VCEL shares (NASDAQ: VCEL)
A recently filed Form 144 by Vericel Corp (VCEL) indicates a proposed sale of 4,375 shares of common stock by Fidelity Brokerage Services LLC, dated June 2, 2026, described as an "option-related sale with cash proceeds." The filing also notes a past sale by Jonathan M. Hopper of 3,472 shares on April 2, 2026, for $121,520.00. This is a procedural disclosure to notify the market of an intended resale of restricted or control stock.
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More
Soleus Capital Management recently bought an additional 1.785 million shares of Vericel (NASDAQ:VCEL), an estimated $63.40 million investment. Despite recent struggles in its stock price, Vericel's revenue climbed 20% year over year, with gross margins expanding and adjusted EBITDA more than doubling. The company also received FDA clearance for a Phase 3 study, indicating potential future growth.
Vericel (VCEL) amends bylaws to reflect new Burlington, MA global headquarters
Vericel Corporation (VCEL) has amended its corporate bylaws to reflect its new global headquarters located at 25 Blue Sky Drive, Burlington, Massachusetts 01803. The amendment was approved by the Board of Directors and became effective on May 18, 2026. This change ensures that the company's official corporate records align with its updated principal executive office address.
Vericel Corporation $VCEL Stock Position Reduced by Truist Financial Corp
Truist Financial Corp reduced its stake in Vericel Corporation ($VCEL) by 59.9% in the fourth quarter, selling 37,035 shares and retaining 24,763 shares valued at approximately $892,000. Despite this reduction, other institutional investors increased their positions, and Vericel's recent quarterly results exceeded expectations with EPS of -$0.12 and revenue of $68.43 million. Analyst sentiment for VCEL remains mixed but generally constructive, with a "Moderate Buy" consensus rating and an average price target of $55.40.
Vericel (VCEL) director McLaughlin exercises options and sells 7,000 shares
Vericel Corp director Kevin F. McLaughlin exercised stock options to acquire 7,000 shares and subsequently sold all 7,000 shares in open-market transactions on May 13, 2026. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 12, 2025. After these transactions, McLaughlin directly held 18,300 shares of Vericel common stock.
Vericel director Paul Wotton sells $327,425 in company stock By Investing.com
Paul K. Wotton, a director at Vericel Corp, sold 10,000 shares of the company's common stock for a total of $327,425 on May 11, 2026. The stock traded between $32.64 and $33.05 per share, and following the sale, Wotton directly holds 18,802 shares. Despite a recent decline of over 10% in the past week, InvestingPro analysis indicates that the $1.68 billion biotech company is undervalued based on its Fair Value assessment.
Vericel director Paul Wotton sells $327,425 in company stock
Vericel director Paul Wotton sold 10,000 shares of Vericel Corp (NASDAQ:VCEL) common stock for $327,425 on May 11, 2026, with the shares trading between $32.64 and $33.05. Despite this sale and a recent stock decline, InvestingPro suggests the company is undervalued. Vericel also reported strong Q1 2026 financial results, exceeding revenue and EPS expectations.
Director Paul K. Wotton sells 10,000 Vericel (VCEL) shares around $33
Vericel director Paul K. Wotton sold a total of 10,000 shares of common stock in open-market transactions on May 11, 2026. The sales were executed in two separate transactions at prices of $32.64 and $33.05 per share, amounting to a net sale of $327,425. Following these transactions, Wotton's direct holdings in Vericel Common Stock total 26,302 shares.
Issuer (NASDAQ: VCEL) notifies sale of 7,000 common shares
Vericel Corporation (NASDAQ: VCEL) has filed a Form 144 notice to sell 7,000 shares of common stock through Fidelity Brokerage Services LLC on May 13, 2026. These shares originate from two option grants issued in 2017 and 2018, each for 3,500 shares. The filing is a regulatory intent to sell and does not provide details on sale proceeds or full seller identity.
[144] Vericel Corp SEC Filing
This article details a Form 144 SEC filing by Vericel Corp (VCEL) regarding a proposed sale of securities. An individual is selling 10,000 shares of common stock, valued at $327,425.00, acquired on May 11, 2021, through a stock option exercise. The sale is scheduled for May 11, 2026, on NASDAQ, and Oppenheimer & Co Inc is handling the transaction.
Vericel Corporation (NASDAQ:VCEL) Q1 2026 Earnings Call Transcript
Vericel Corporation (NASDAQ:VCEL) reported a strong Q1 2026, with total revenue exceeding $68 million, a 30% increase year-over-year, driven by substantial growth in both MACI and the Burn Care business. The company raised its full-year 2026 revenue guidance by $10 million to a range of $326 million to $336 million, citing strong Q1 performance, continued business momentum, and expected NexoBrid BARDA procurement revenue. Discussions also covered the successful expansion of the MACI sales force, the growing adoption and positive early data for MACI Arthro, and the long-term potential of the BARDA award for NexoBrid, while dismissing competitive threats from other cartilage repair products.
Insider Sell: Mara Joseph Anthony Jr Sells 5,000 Shares of Veric
Mara Joseph Anthony Jr, CFO of Vericel Corp (VCEL), recently sold 5,000 shares, reducing his holdings to 21,009 shares. Over the past year, there have been 17 insider sells and no insider buys at Vericel. The stock, trading at $40.50, is considered significantly undervalued against its GF Value of $50.42, despite a higher-than-industry price-earnings ratio.
Vericel (NASDAQ: VCEL) accounting chief sells 4,855 shares
Vericel's Principal Accounting Officer, Jonathan Siegal, sold a total of 4,855 shares of company common stock in open-market transactions on May 6 and May 7, 2026. These sales, valued at $188,045, were pre-arranged under a Rule 10b5-1 trading plan adopted in December 2025. Following these transactions, Siegal directly holds 1,118 shares of Vericel common stock.
Vericel (VCEL) CFO 10b5-1 sale leaves 21,009 shares held
Vericel Corp's CFO, Mara Joseph Anthony Jr, completed an automatic open-market sale of 5,000 shares of common stock at $40.50 per share on May 7, 2026. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 2, 2025. Following the sale, the CFO retains 21,009 shares, including those acquired through the company’s 2015 Employee Stock Purchase Plan.
Vericel Corp reports results for the quarter ended March 31 - Earnings Summary
Vericel Corp has released its earnings summary for the quarter that ended on March 31. The report contains the financial results for the specified period. This news was originally reported by Reuters and published on TradingView.
Vericel Corp 1Q 2026: Revenue $68.43M, EPS ($0.12) — 10-Q Summary
Vericel Corp (VCEL) reported its first-quarter 2026 results, showing revenue of $68.43 million, a 30.1% increase year-over-year from $52.6 million. The company narrowed its net loss to $6.3 million, or diluted EPS of ($0.12), significantly improving from a net loss of $11.25 million, or diluted EPS of ($0.23), in the prior year. Growth was mainly driven by strong sales of MACI and Epicel, alongside progress in MACI Arthro commercialization and clinical pipeline developments.
[144] Vericel Corp SEC Filing
Vericel Corporation has filed a Form 144 notice proposing the sale of 5,000 shares of common stock, valued at $202,500.00, through Fidelity Brokerage Services LLC. The filing, dated May 7, 2026, details that these shares stem from restricted stock vesting events occurring in February 2025. This regulatory document provides transparency into potential insider sales.
BARDA burns contract backs NexoBrid growth at Vericel (VCEL)
Vericel Corporation (VCEL) reported strong first-quarter 2026 results with revenue up 30% to $68.4 million, driven by growth in MACI and Epicel sales, while net loss narrowed to $6.3 million. The company reinforced its financial position with $210.6 million in cash and investments and no outstanding debt on its $150 million revolving credit facility. A significant development was a ten-year, up to $196.9 million agreement with BARDA for NexoBrid procurement and development, aiming to expand its burn care franchise.
Vericel Reports Q1 2026: Revenue Up 30% to $68.4M, Adjusted EBITDA $9.6M
Vericel reported strong first-quarter 2026 results, with total net revenue increasing 30% to $68.4 million and adjusted EBITDA reaching $9.6 million. The company's gross margin was 72%, and it recorded a net loss of $6.3 million, alongside a healthy free cash flow of $15.1 million. Vericel raised its full-year 2026 revenue guidance to $326–$336 million, driven by significant growth in both MACI and Burn Care segments and FDA approval for MACI commercial manufacturing at its new facility.
Vericel Corporation Reports 30% Revenue Growth to $68.4 Million in Q1 2026, Raises Full-Year Guidance to $326-$336 Million
Vericel Corporation reported a strong first quarter in 2026, with total revenue increasing by 30% to $68.4 million, driven by significant growth in both its MACI and Burn Care segments. The company also announced a 195% increase in adjusted EBITDA to $9.6 million and generated $15.1 million in free cash flow. Consequently, Vericel raised its full-year 2026 revenue guidance by $10 million to a range of $326 to $336 million, expressing optimism for continued growth and cash generation.
